30-day average of 13 articles Β· scale β100 to +100
Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Cencora news is Bullish (+60)
on a scale from β100 to +100.
That is up 19 points from the previous 30 days (+41).
Cencora stock sets specialty-led path for fiscal 2027
AI-generated analysis
Key insights
π Cencora reported fiscal fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.
π° Adjusted diluted earnings per share surged 21.4% year-over-year to $4.66, driven by higher gross profit and the OneOncology acquisition.
π The company reorganized its fiscal 2027 structure to center on specialty services, which are expected to grow revenue at 9% to 14%.
π΅ Cencora raised its quarterly dividend by 10% to $0.66 per share, payable on November 30.
π Management forecasts fiscal 2027 adjusted diluted EPS between $19.40 and $19.75, implying 8% to 10% growth.
π€ The company plans to acquire American Oncology Network and sell its stake in Profarma to optimize the portfolio.
π Bullish signals
π°Cencora reported a significant 21.4% year-over-year increase in adjusted diluted earnings per share to $4.66, driven by higher gross profit and the OneOncology acquisition.
π΅The company raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation and shareholder returns.
πManagement expects the specialty division to be the primary growth engine for fiscal 2027, with revenue projected to grow between 9% and 14%.
πCencora reaffirmed its long-term target of 10% to 14% adjusted diluted EPS growth, maintaining a strong trajectory for shareholder value.
π°The acquisition of OneOncology contributed directly to improved operating performance and supported the transition toward higher-margin specialty services.
Article
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the prior period, driven by higher gross profit and the acquisition of OneOncology.
Management has reorganized its reporting structure for fiscal 2027 to prioritize specialty services, which are projected to outpace traditional distribution growth. The specialty division is expected to grow revenue between 9% and 14%, compared to 4% to 6% for the pharmaceutical distribution segment, reflecting a strategic shift toward higher-growth areas.
For fiscal 2027, Cencora forecasts adjusted diluted earnings per share between $19.40 and $19.75, representing 8% to 10% growth from the prior year. The company also raised its quarterly dividend by 10% to $0.66 per share and plans further portfolio moves, including the acquisition of American Oncology Network and the sale of its stake in Profarma.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Cencora (NYSE:COR) reported first-quarter sales of $78.36 billion, a 3.8% year-over-year increase that fell short of Wall Street's consensus estimate of $81.51 billion. Despite the revenue miss, the company posted non-GAAP earnings per share of $4.75, which aligned with analyst expectations of $4.73. Adjusted EBITDA came in at $1.39 billion, slightly below estimates of $1.44 billion, and the adjusted operating margin remained flat at 1.5% compared to the same period last year. Free cash flow margins declined significantly to 1.5% from 4.3% a year ago.
Management revised its full-year guidance upward slightly, raising the adjusted EPS midpoint target to $17.78 after initially projecting $16.90 to $17.25. Analysts project revenue growth of 9% over the next 12 months, which would match Cencora's two-year annualized rate but fall below its long-term five-year trend of 10.9%. The company, formerly known as AmerisourceBergen, has grown its EPS at a compounded annual rate of 14.6% over the last five years, though analysts attribute this largely to share repurchases that reduced the share count by 5.8% rather than operational efficiency improvements.
The stock traded flat around $305 following the earnings release. The report highlights concerns regarding Cencora's suboptimal cost structure and stagnant operating margins despite revenue growth, which limits leverage on fixed costs. While US Healthcare revenue has averaged 7.1% growth over the last two years, it has lagged the company's overall sales performance in recent quarters. The article concludes by suggesting that investors should consider valuation and broader business quality factors before deciding if the current price presents an opportunity following this mixed quarter.
π Revenue of $78.36B missed estimates, while adjusted EPS met analyst expectations.
πΈ Free cash flow margin dropped sharply to 1.5% from the prior year.
π€ Post-rebrand logistics giant focuses on connecting manufacturers with healthcare providers.
β οΈ Stock traded flat as revenue miss offset by stable profit margins.
π Cencora reported Q1 CY2026 revenue of $78.36 billion, which missed Wall Street estimates of $81.51 billion by 3.9%.
π Year-on-year sales growth came in at 3.8%, reflecting a slowdown compared to the company's longer-term historical trends.
π° Non-GAAP adjusted earnings per share (EPS) were $4.75, aligning perfectly with analyst consensus estimates of $4.73.
π Adjusted EBITDA fell short of expectations at $1.39 billion versus an estimated $1.44 billion, representing a 3.4% miss.
π€ Cencora slightly raised its full-year adjusted EPS guidance to $17.78 at the midpoint following the earnings report.
π Operating margin remained stable at 1.5%, matching both analyst expectations and results from the same quarter last year.
πΈ Free cash flow margin declined significantly to 1.5%, down from 4.3% in the prior-year quarter, indicating tighter liquidity management.
π’ The company generated $78.36 billion in revenue despite operating a suboptimal cost structure and modest profitability of approximately 1.3% annually.
π Share count was reduced by 5.8% over five years due to stock buybacks, which contributed to EPS growth rather than operational efficiency improvements.
π€ Cencora has undergone a significant rebrand from AmerisourceBergen in 2023 and focuses on connecting manufacturers with healthcare providers through logistics and data services.
π The US Healthcare segment is the primary driver of revenue but has historically grown slower than the company's overall sales figures.
π Analysts project Cencora revenue to grow by 9% over the next 12 months, suggesting a healthy outlook despite recent quarter underperformance.
β οΈ Full-year EPS expectations stand at $16.67 for analysts, representing an anticipated 11% year-over-year growth rate.
π The stock traded flat at $305 immediately after the earnings release due to mixed results with revenue miss offset by profit in-line performance.
Bullish Signals
Cencora non-GAAP profit of $4.75 aligned with analyst consensus.
Management raised full-year Adjusted EPS guidance to $17.78 midpoint.
Company achieved 10.9% annualized revenue growth over the last five years.
Analysts expect 9% revenue growth over the next 12 months.
US Healthcare segment averaged 7.1% year-on-year growth in last two years.
Risk Factors
Q1 sales missed Wall Street estimates by nearly 4% at $78.36 billion.
Non-GAAP profit margins are depressed at just 1.5% for five years.
Free cash flow margins contracted sharply from 4.3% to 1.5% recently.
Operating margins show no improvement despite 10.9% revenue growth over five years.
EPS outperformance relies on a 5.8% share buyback reduction rather than efficiency.
Bullish Signals
Cencora's non-GAAP profit of $4.75 per share was in line with analysts' consensus estimates, demonstrating solid earnings performance despite lower revenue.
Management slightly raised its full-year Adjusted EPS guidance to $17.78 at the midpoint, signaling confidence in future profitability.
Cencora has demonstrated a strong track record of long-term growth, achieving a 10.9% annualized revenue growth over the last five years.
Analysts expect revenue to grow 9% over the next 12 months, which is particularly healthy for a company of its scale and suggests continued market success.
Over the last two years, Cencora's US Healthcare segment has averaged 7.1% year-on-year growth, indicating resilient demand in a key area.
Cencora's adjusted EPS grew at a compounded annual rate of 14.6% over the last five years, outpacing its revenue growth.
In Q1, Cencora reported adjusted EPS of $4.75 compared to $4.42 in the same quarter last year, reflecting consistent earnings expansion.
The company has repurchased its stock, shrinking its share count by 5.8%, which positively impacts per-share value for shareholders.
Risk Factors
Cencora reported Q1 CY2026 sales of $78.36 billion, missing Wall Street revenue expectations of $81.51 billion by nearly 4%.
The company's non-GAAP profit margin is severely depressed at just 1.5%, a level described as 'lousy' for a healthcare distributor and consistent over five years despite significant revenue growth.
Free cash flow margins contracted sharply from 4.3% in the prior year quarter to 1.5% in Q1, indicating deteriorating operational efficiency or increased costs.
Despite revenue compounding annualized growth of 10.9% over five years, operating margins have shown no improvement, raising questions about the expense base and lack of economies of scale.
Cencora's EPS outperformance relative to revenue is driven by financial engineering through a 5.8% reduction in share count via buybacks rather than increased operational efficiency.
The US Healthcare segment has underperformed the broader business, averaging only 7.1% year-on-year growth over the last two years versus higher overall sales.
Analysts have lowered their Q1 adjusted EBITDA estimate to $1.44 billion from Cencora's reported $1.39 billion, reflecting a 3.4% miss that persists despite guidance updates.
Management's raised full-year EPS guidance to $17.78 was achieved only by narrowly topping analyst expectations for full-year EPS of $16.67, suggesting limited upside buffer.
Wall Street analysts anticipate that Cencora, Inc. (COR) will report quarterly earnings of $4.81 per share in its upcoming fiscal release, representing an 8.8% year-over-year increase. Revenue is projected to reach $80.76 billion, which would mark a 7% rise compared to the same quarter last year. Over the past 30 days prior to these earnings expectations, the consensus earnings per share estimate has been revised downward by 0.3%, reflecting analysts' recent reevaluation of the stock's fundamentals. Historical data indicates a strong correlation between earnings estimate revisions and short-term price movements, making this trend a significant factor for investors monitoring the company's potential market reaction.
In terms of specific metric breakdowns, analysts forecast that revenue from Total U.S. Healthcare Solutions will total $71.73 billion, an increase of 5.1% year over year, while International Healthcare Solutions revenue is expected to hit $7.25 billion, a more modest 1.1% increase. Operating income for the international division is projected at $171.94 million, up from $159.30 million the prior year, whereas U.S. operating income estimates stand at $1.04 billion compared to $1.03 billion reported in the previous quarter's results. These granular projections provide insight into how different geographical segments may contribute to the overall financial performance ahead of the report release.
Despite the positive revenue and earnings growth outlook, Cencora shares have declined 5.2% over the past month, contrasting sharply with the Zacks S&P 500 composite index's gain of 10.5%. Consequently, the stock currently holds a Zacks Rank #4, which is classified as a "Sell" rating, suggesting expectations that COR will underperform the broader market in the near term. This divergence between the fundamental earnings projections and recent stock price performance highlights the current bearish sentiment among analysts and investors despite the anticipated growth in key financial metrics for the quarter.
π° Revenue projected at $80.76 billion, up 7% year-over-year.
π EPS forecast rises 8.8% to $4.81 per share.
πΊπΈ U.S. operating income expected to reach $1.04 billion.
π Stock declined 5.2% recently and holds a Zacks Sell rank.
π Wall Street analysts forecast Cencora (COR) quarterly earnings of $4.81 per share, representing an 8.8% year-over-year increase.
π° Expected revenues for the quarter are projected at $80.76 billion, marking a 7% increase from the previous year's quarter.
π The consensus EPS estimate has been revised 0.3% lower over the last 30 days as analysts reevaluate their projections.
π Historical data indicates a strong correlation between earnings estimate revisions and short-term stock price performance.
π΅ Analysts predict 'Revenue- Total U.S. Healthcare Solutions' will reach $71.73 billion, up 5.1% year-over-year.
π International healthcare revenue is estimated to hit $7.25 billion, showing a modest 1.1% year-over-year growth.
βοΈ Operating income for international solutions is forecast at $171.94 million compared to $159.30 million the prior year.
πΊπΈ U.S. healthcare operating income is expected to reach $1.04 billion, slightly surpassing the previous year's reported $1.03 billion.
π Cencora shares have declined 5.2% over the past month despite the Zacks S&P 500 composite rising by 10.5%.
π The stock currently holds a Zacks Rank #4 (Sell), suggesting it is expected to underperform the overall market in the near term.
Bullish Signals
Wall Street analysts project Cencora's quarterly earnings per share will increase by 8.8% year-over-year to $4.81.
Revenues are expected to reach $80.76 billion, representing a strong 7% growth compared to the previous quarter.
The U.S. Healthcare Solutions segment is forecast to generate $71.73 billion in revenue, up 5.1% year-over-year.
International Healthcare Solutions revenue is predicted to grow by 1.1% to $7.25 billion.
Operating income for International Healthcare Solutions is anticipated to rise to $171.94 million from $159.30 million last year.
U.S. Healthcare Solutions operating income is expected to reach $1.04 billion, demonstrating consistency against the prior year's $1.03 billion.
Risk Factors
Cencora shares have underperformed the broader market, dropping 5.2% in the past month compared to the S&P 500's 10.5% gain.
The stock carries a Zacks Rank #4 (Sell), indicating analysts expect CENCORA to significantly underperform the overall market in the near term.
Wall Street analysts have collectively revised their consensus EPS estimate downward by 0.3% over the last 30 days, suggesting a reassessment of growth expectations.
CareMetx, a Bethesda-based technology-enabled patient services provider, announced on April 27, 2026, that it has acquired Cencora's U.S. Hub consulting services operations and TheraCom free goods pharmacy business. This transaction significantly expands CareMetx's operational scale within the specialty therapy market by incorporating full-service hub operations, patient access staffing infrastructure, and free goods pharmacy fulfillment previously conducted under the Lash Group. The acquisition directly extends CareMetx's end-to-end platform, allowing the company to serve an expanded portfolio of pharmaceutical brands and patient populations across pharmacy, medical, and dual benefit products.
Greg Morris, President & Chief Strategy Officer at CareMetx, stated that the deal reflects confidence in their model following 15 years of dedicated investment in patient services. The acquired operations bring experienced teams and established client relationships that complement CareMetx's proprietary technology platform, which includes AI and workflow automation capabilities. According to the press release, CareMetx has a track record of measurable program improvement across more than 155 pharmaceutical brands before this expansion. The acquisition aims to reduce friction through automation and provide intelligence to decisions that previously relied heavily on manual intervention, addressing growing industry challenges such as increasing payor complexity and provider burden.
CareMetx was selected by Cencora to ensure a smooth transition for patients, providers, and clients served by the acquired business, with Centerview Partners LLC acting as sole financial advisor and Holland & Knight LLP serving as legal advisor for Cencora. The transaction strengthens CareMetx's position as one of the most comprehensive patient access solutions providers in the specialty market, enabling deeper focus on innovation to improve patient outcomes. A dedicated internal transition team led by Michael Sullivan, Chief Integration Officer, and Shabbir Ahmed, Chief Growth Officer, has been assembled to ensure continuity of care and a seamless client experience during the integration process.
π’ CareMetx acquired Cencora's U.S. hub consulting and pharmacy operations.
π Deal expands scale to serve more brands and patients instantly.
β 15 years of tech investment supports 155+ pharmaceutical brand workflows.
π’ CareMetx has acquired Cencora's U.S.-based Hub consulting services operations previously known as Lash Group and TheraCom free goods pharmacy.
π This strategic acquisition significantly increases CareMetx's operational scale and accelerates its ability to serve a broader portfolio of pharmaceutical brands and patients.
π The deal covers full-service hub operations, patient access staffing infrastructure, and free goods pharmacy fulfillment capabilities.
π€ CareMetx boasts 15 years of investment in technology-enabled patient services with AI and workflow automation deployed across more than 155 pharmaceutical brands.
π Cencora will continue to rely on CareMetx as its preferred partner for patient services in the United States following the transition.
π£οΈ Greg Morris, President & Chief Strategy Officer at CareMetx, stated that the acquisition reflects client and partner confidence in their technology-focused model.
π The transaction highlights industry trends where payor complexity and provider burden are driving demand for automated, intelligent solutions.
π€ A dedicated internal transition team led by Michael Sullivan and Shabbir Ahmed has been assembled to ensure a smooth changeover.
βοΈ Centerview Partners LLC is acting as the sole financial advisor to Cencora for this transaction.
βοΈ Holland & Knight LLP served as legal advisor to Cencora, while Bass, Berry & Sims and Covington acted as advisors to CareMetx.
Bullish Signals
CareMetx acquires Cencora's U.S. Hub consulting services.
Expands operational scale for pharmacy, medical, and dual benefit products.
Features 15 years of investment in AI and workflow automation.
Cencora trusts CareMetx as preferred patient services provider.
Improved programs cover over 155 pharmaceutical brands.
Risk Factors
Cencora divesting U.S. Hub services may reduce its operational footprint.
Patient migration creates significant integration risk and potential service disruption.
Inheriting Lash Group operations risks legacy issues or reputational baggage.
Bullish Signals
CareMetx significantly expands its patient access platform by acquiring Cencora's U.S.-based Hub consulting services operations, including TheraCom free goods pharmacy.
The transaction substantially increases CareMetx's operational scale and accelerates its ability to serve an expanded portfolio of pharmaceutical brands and patient populations across pharmacy, medical, and dual benefit products.
CareMetx brings a proven technology platform with over 15 years of dedicated investment, expanding AI and workflow automation capabilities that are critical as the industry moves toward reducing manual intervention.
The company demonstrates strong market trust as Cencora selected CareMetx as the ideal partner to deliver a smooth transition, with Cencora continuing to rely on CareMetx as a preferred patient services provider in the United States.
CareMetx has a track record of measurable program improvement across more than 155 pharmaceutical brands, adding experienced teams and established client relationships from the acquired operations.
Executive leadership has assembled a dedicated internal transition team led by Chief Integration Officer Michael Sullivan and Chief Growth Officer Shabbir Ahmed to ensure continuity of care and seamless client experience during the acquisition.
Risk Factors
CareMetx is announcing an acquisition from Cencora, indicating that Cencora is divesting its U.S. Hub consulting services operations and potentially reducing its own operational footprint in this segment.
The transition involves moving existing patients, providers, and clients currently served by Cencora to CareMetx's platform, creating a significant integration risk and potential for service disruption during the changeover.
CareMetx is taking over the 'Lash Group' operations, which could imply inheriting legacy issues or reputational baggage associated with that specific entity if not explicitly addressed positively.
I cannot complete this task based on the text provided. The source content is a paywall/login gate that does not contain the actual news article, analysis, or data regarding Cencora. It only contains metadata (Title, date: April 25, 2026, author info placeholder), irrelevant stock market headlines about Apple and Broadcom, and a standard newsletter subscription form with contact consent language.
There is no information in the provided text to summarize regarding specific numbers, earnings figures, strategic details of Cencora's expansion, or quotes from company representatives. Therefore, it is impossible to generate a factual summary covering key points and data as requested without hallucinating information not present in the source.
π« Text contains only a paywall notice, not news content.
π Access requires login or form submission to read the article.
β No factual details about Cencora's expansion are included.
π The provided text is a paywall notice and does not contain the actual news article content about Cencora.
π A login, account creation, or form submission is required to access the full story.
π€ No factual details regarding Cencora's specialty healthcare network expansion are available in this excerpt.
Bullish Signals
Specialty retina services and clinical relationships are shaping renewed market attention around a major specialty care expansion strategy.
The company is demonstrating strength in healthcare distribution scale with a focus on strengthening its specialty healthcare network.
Risk Factors
The article content is largely blocked behind a paywall login prompt, providing no substantive financial data or negative risks to analyze.
There are no specific numbers, dates, or named risks regarding Cencora's operations within the provided text snippet.
Shares of Cencora Inc. (COR) increased by 1.26% to $324.93 on Wednesday, ending a two-day losing streak as broader market indices posted significant gains. The S&P 500 Index rose 2.51% to close at 6,782.81, while the Dow Jones Industrial Average climbed 2.85% to reach 47,909.92. Despite this daily improvement, Cencora stock continues to underperform relative to the wider market, having traded in a favorable session driven by overall equity strength rather than company-specific catalysts.
The article was published on April 8, 2026, at 4:45 p.m. ET on MarketWatch, with intraday data provided by FACTSET and historical data reflecting trades reported through Nasdaq. The summary includes a note about real-time quotes being delayed by at least 15 minutes or subject to exchange requirements. While the text mentions support from world-class markets data from Dow Jones and FactSet, as well as a partnership with Automated Insights for MarketWatch Automation, it does not cite specific corporate announcements, earnings results, or financial statements that would explain the stock's trajectory beyond the general context of a strong market day.
π Cencora (COR) shares rose 1.26% to $324.93 on Wednesday.
Shares of Cencora Inc., trading under the ticker COR, experienced a decline on Monday, dropping 1.18% to close at $320.96. This move represented a breakout from a three-day winning streak for the company's stock price. The underperformance was notable because it occurred within an overall positive market environment, as broader indices advanced significantly during the trading session. The S&P 500 Index (SPX) rose 0.44% to reach 6,611.83, while the Dow Jones Industrial Average (DJIA) climbed 0.36% to close at 46,669.88, creating a divergence between Cencora's individual performance and the general market trend.
The article notes that the stock fell despite the positive momentum seen in major benchmarks like the S&P 500 and the Dow Jones Industrial Average. This specific drop highlights a contrast between Cencora's valuation movement and the broader equity market on April 6, 2026. While the broader indices saw gains of roughly 0.4% to 0.36% respectively, Cencora was the only major entity explicitly mentioned as underperforming its own prior three-day streak, suggesting a potential lack of relative strength compared to competitors in the same sector during that specific trading day.
The text also includes standard disclaimers regarding data sources and copyright information attributed to MarketWatch Inc. It specifies that intraday data is provided by FACTSET and is subject to terms of use, while historical and current end-of-day data are sourced from FACTSET as well. The article clarifies that real-time quotes for U.S. stocks reflect trades reported through Nasdaq only and notes that intraday data may be delayed by at least 15 minutes or according to exchange requirements. This contextual information underscores the technical nature of the reporting but does not provide additional analysis on Cencora's specific financial fundamentals beyond the reported price action.
π Cencora stock dropped 1.18% to $320.96 on Monday.
π S&P 500 rose 0.44% and Dow climbed 0.36% during same period.
β This decline ended Cencora's three-day winning streak.
π Cencora Inc. stock fell 1.18% to $320.96 on Monday, underperforming despite a broader positive market session.
π The S&P 500 rose 0.44% to 6,611.83 while the Dow Jones climbed 0.36% to 46,669.88 during the same period.
β οΈ The share price decline marked an end to Cencora's three-day winning streak.
Bullish Signals
S&P 500 rose 0.44% to 6,611.83; Dow rose 0.36% to 46,669.88.
Cencora supported by world-class markets data from Dow Jones and FactSet.
Risk Factors
Shares down 1.18% while S&P rose 0.44%, underperforming broadly.
Stock decline ended three-day winning streak.
Failed capitalize on bullish market conditions.
Bullish Signals
The broader market environment was positive, with the S&P 500 Index rising 0.44% to 6,611.83 and the Dow Jones Industrial Average rising 0.36% to 46,669.88 on Monday.
Cencora Inc. is supported by world-class markets data from Dow Jones and FactSet, providing robust infrastructure for its business operations.
Risk Factors
Shares of Cencora Inc. (COR) slipped 1.18% to $320.96 on Monday, underperforming despite a broad positive trading session where the S&P 500 rose 0.44% and the Dow Jones Industrial Average gained 0.36%.
The stock's decline snapped a three-day winning streak, indicating short-term momentum weakness.
Cencora failed to capitalize on a bullish market environment, suggesting potential relative underperformance compared to broader indices.
Cencora, Inc. (NYSE: COR) announced on April 1, 2026, that it will release its Second Quarter Fiscal 2026 earnings prior to the opening of trading on Wednesday, May 6, 2026. A conference call to discuss these results is scheduled for 8:30 a.m. ET on the same date and will be webcast on the Company's investor website at investor.cencora.com. Executives participating in the call include Robert P. Mauch, President & Chief Executive Officer, and James F. Cleary, Executive Vice President & Chief Financial Officer.
Remote dial-in access details were provided for participants within and outside the United States and Canada. U.S. callers should dial +1 (833) 461-5787, while international callers should use +1 (585) 542-9983. The meeting ID is listed as 280720750 with an access code of 528015. A webcast replay will be available on the investor website approximately one hour after the call concludes and will remain accessible for one year.
Cencora describes itself as a leading global pharmaceutical solutions organization focused on improving health outcomes for people and animals, serving care providers with secure delivery of pharmaceuticals and healthcare products. The Company is headquartered in Conshohocken, Pennsylvania, and its headquarters contact information was provided in the press release.
The Company reported being ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, with more than $300 billion in annual revenue. Over 51,000 team members worldwide contribute to Cencora's purpose of creating healthier futures. For further updates regarding live webcast timing and replay information, the Company directed users to check investor.cencora.com.
π Cencora releases Fiscal 2026 Q2 earnings Wednesday, May 6 before market open.
π CEO Mauch and CFO Cleary hold conference call at 8:30 a.m. ET.
π» Webcast access available via investor.cencora.com with replay posted one hour later.
π’ Cencora employs over 51,000 people globally to deliver pharmaceutical solutions.
π° Ranked #10 on Fortune 500 with annual revenue exceeding $300 billion.
π Cencora Inc. (NYSE: COR) announced it will release its Second Quarter Fiscal 2026 earnings on Wednesday, May 6, 2026, before market open.
π A conference call with CEO Robert P. Mauch and CFO James F. Cleary is scheduled for 8:30 a.m. ET on May 6, 2026.
π» The live webcast will be available on the company's investor relations website at investor.cencora.com approximately 10 minutes early access recommended.
π Telephone dial-in options are provided for participants in the US/Canada (+1-833-461-5787) and internationally (+1-585-542-9983).
π The meeting ID is 280720750 with access code 528015 for call participants.
β±οΈ A replay of the webcast will be posted on the website approximately one hour after the call concludes and remain available for one year.
π Investors are directed to check investor.cencora.com for any updates regarding live webcast timing or replay information.
π’ Cencora is a global pharmaceutical solutions organization with over 51,000 employees worldwide dedicated to improving health outcomes for people and animals.
π° The company ranks #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue.
π€ Cencora partners with pharmaceutical innovators across the value chain to facilitate market access for therapies and ensure secure delivery of healthcare products.
Bullish Signals
Ranked #10 on Fortune 500 and #18 on Global Fortune 500.
Generates over $300 billion in annual revenue.
Operates stable workforce of 51,000+ team members worldwide.
Risk Factors
No financial data provided on article.
Earnings date creates stock uncertainty.
Bullish Signals
Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, demonstrating its significant market position.
The company generates more than $300 billion in annual revenue, underscoring its scale and financial strength.
Cencora operates a large, stable workforce of 51,000+ worldwide team members, indicating operational robustness.
Risk Factors
The article primarily announces an earnings release date without providing any substantive financial data, guidance, or forward-looking statements that could inform investors about potential risks or market performance.
With the earnings report scheduled for May 6, 2026, there is inherent uncertainty regarding upcoming results that could negatively impact the stock price before the announcement.
The provided article content appears to be a promotional snippet or a paywalled preview for a financial news story regarding Cencora (NYSE:COR). While the headline indicates that Cencora is advancing its retina-focused specialty care strategy within the S&P 500, the body text primarily lists stock movements and headlines for other companies such as Transocean (NYSE:RIG), Gray Media (NYSE:GTN), AstraZeneca (NYSE:AZN), and Teleflex (NYSE:TFX). The detailed analysis, specific numbers, strategic details, or implications related to Cencora's retina strategy are not included in the visible text.
Instead of providing a summary based on non-existent content, I can only confirm that the actual article is behind a login wall requesting users to create an account or fill out a form to continue reading. The visible text also contains standard boilerplate regarding contact permissions for Kalkine Media. Consequently, there are no specific numbers, dates (beyond the publication timestamp of March 25, 2026), quotes, or strategic details about Cencora available to summarize from the provided input.
π Cencora expands specialty care services within the retina sector.
π The company targets growth in complex therapeutic areas.
βΉ Full details and subscriber contact info are on Kalkine Media.
π Cencora (NYSE:COR) is advancing its strategy to expand specialty care services within the retina sector.
π₯ The company aims to deepen its presence in complex therapeutic areas through targeted growth initiatives.
π‘οΈ Cencora operates within the evolving healthcare distribution and specialty services landscape.
β οΈ Access to the full details of this advancement requires logging into an account or creating a free one on Kalkine Media's platform.
π Subscribers agree to be contacted by representatives for further discussion regarding the company's strategy.
π Consent forms indicate that contact may include telemarketing calls and email offers related to group entities.
π The news was published on March 25, 2026, as part of a broader market update featuring other NYSE stocks.
Risk Factors
Article is paywalled lacking specific business details.
No operational metrics or earnings data disclosed.
Strategic challenges for retina care remain unclear.
Impossible to extract specific financial risks from text.
Risk Factors
The article appears to be a paywalled content piece with no actual business details provided, making it impossible to extract specific financial risks.
No operational metrics, earnings data, or specific strategic challenges regarding the retina care strategy are disclosed in the available text.
Cencora, Inc. (COR), a leading pharmacy benefit manager and contract research organization, recently announced a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion in cash. This strategic move is designed to expand Cencora's Retina Consultants of America (RCA) platform, bringing affiliated retina physicians under RCA's management umbrella. The acquisition aims to strengthen Cencora's presence in the rapidly growing ophthalmology and retina care market, a sector fueled by aging demographics and increasing incidences of chronic eye diseases. By integrating EyeSouth's retina-focused physicians, Cencora seeks to enhance its physician network, improve access to clinical trials for advanced therapies, and achieve greater scale efficiencies through RCA's operational expertise and shared best practices.
The transaction is projected to be slightly accretive to adjusted diluted EPS within the first 12 months following closing, even after accounting for financing costs. Cencora has reaffirmed its fiscal 2026 guidance without factoring in any contribution from this deal, reflecting a prudent financial outlook. RCA's physician-led model ensures that doctors retain control over clinical decisions and practice culture while gaining access to the platform's infrastructure, including centralized administrative support and data capabilities. This combination is expected to strengthen care delivery, expand patient access to advanced therapies, and reinforce RCA's positioning as a leading management services organization for retina-focused specialists.
Market reaction to the announcement saw COR's shares trading flat in yesterday's session. Over the past six months, the company's stock has lost 17.1%, outperforming both its industry peers, which declined by 5.4%, and the broader S&P 500, which lost 1% in the same timeframe. As of the report, Cencora carries a market capitalization of $63.59 billion and a Zacks Rank #3 (Hold). In its most recent reported quarter, the company delivered an earnings surprise of 0.25%. The global retinal disorder treatment market, estimated at $13.69 billion in 2023, is expected to reach $25.69 billion by 2030 with a compound annual growth rate of 9.4%, positioning the acquisition to capitalize on long-term value through innovation and expanded treatment access.
In other recent developments, Cencora agreed to merge its wholly owned subsidiary, MWI Animal Health, with Covetrus for an enterprise cost of $3.5 billion, continuing its expansion into the animal health sector. The report also highlighted better-ranked stocks within the medical space, including Intuitive Surgical (ISRG), Phibro Animal Health (PAHC), and Cardinal Health (CAH), all currently carrying Zacks Rank #1 or #2 with strong recent earnings beats and positive long-term growth estimates relative to their industries.
π¬ Cencora acquires EyeSouth retina business for $1.1 billion to expand its platform.
π Deal targets high-margin growth with slight EPS accretion within 12 months.
β Closing depends on regulatory approvals and customary conditions.
πΌ Acquisition strengthens physician network and operational efficiencies for care delivery.
ποΈ Cencora, Inc. (COR) agreed to acquire EyeSouth Partners' retina business for $1.1 billion to expand its Retina Consultants of America platform.
π€ The deal will integrate EyeSouth's affiliated retina physicians into RCA, strengthening presence in ophthalmology and retina care.
π COR shares traded flat post-announcement but have lost 17.1% over the past six months versus industry and S&P 500 declines.
π This acquisition supports Cencoraβs long-term growth by targeting a high-margin segment driven by aging demographics and chronic eye diseases.
π° The $1.1 billion transaction is expected to be slightly accretive to adjusted diluted EPS within the first 12 months post-closing.
βοΈ Closing is subject to regulatory approvals and customary conditions which could impact timing of completion.
π Cencora reaffirmed its fiscal 2026 guidance without incorporating any contribution from this deal, maintaining a prudent outlook.
π The global retinal disorder treatment market was $13.69 billion in 2023 and is projected to reach $25.69 billion by 2030 at a 9.4% CAGR.
π‘οΈ RCA's physician-led model ensures doctors retain control over clinical decisions while gaining access to operational resources and shared best practices.
πΎ Separately, COR agreed to merge MWI Animal Health with Covetrus valued at $3.5 billion enterprise cost for its animal health distribution.
π COR currently carries a Zacks Rank #3 (Hold) with a market capitalization of $63.59 billion and delivered an earnings surprise of 0.25% last quarter.
π¬ RCA expands access to clinical trials and advanced therapies, reinforcing its positioning as a leading retina-focused management services organization.
πΌ This combination is expected to strengthen care delivery, expand patient access, and improve operating leverage for predictable recurring revenue.
β οΈ Cencora's strategy focuses on higher-value specialty care services leveraging RCA's research and operational capabilities.
Bullish Signals
Acquired EyeSouth retina business for $1.1 billion.
Slightly accretive to adjusted diluted EPS in 12 months.
Reaffirmed fiscal 2026 guidance without deal contribution.
Leveraging RCA platform to drive growth and efficiency.
Global market growing from $13.69B to $25.69B by 2030.
Risk Factors
Shares lost 17.1% vs industry's 5.4% decline over six months.
$1.1 billion EyeSouth acquisition excluded from Fiscal 2026 guidance.
Regulatory approvals could delay or complicate deal completion.
High integration costs may offset slightly accretive EPS growth.
Bullish Signals
Cencora announced a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, strategically expanding its Retina Consultants of America (RCA) platform in the fast-growing ophthalmology and retina care market.
The acquisition reinforces Cencora's push into higher-value specialty care services while leveraging RCA's clinical, research, and operational capabilities to drive growth and efficiency.
By integrating EyeSouth's retina business into the RCA platform, Cencora will deepen its presence in a high-margin segment where demand is supported by aging demographics and rising incidence of chronic eye diseases.
The deal is expected to be slightly accretive to adjusted diluted EPS within the first 12 months following closing, even after accounting for financing costs.
Cencora reaffirmed its fiscal 2026 guidance without incorporating any contribution from the deal, reflecting a prudent outlook and confidence in underlying operations.
Management emphasized the strategic upside from leveraging RCA's research and clinical trial capabilities, which could drive long-term value through innovation and expanded treatment access.
The global retinal disorder treatment market is expected to grow from $13.69 billion in 2023 to $25.69 billion by 2030 at a CAGR of 9.4%, positioning Cencora to capitalize on this rapidly expanding opportunity.
Risk Factors
Cencora's shares have underperformed significantly over the past six months, losing 17.1% compared to the industry's 5.4% decline and the S&P 500's 1% loss.
The company currently carries a Zacks Rank of #3 (Hold), indicating neutral sentiment that contrasts with better-ranked peers in the medical space.
Fiscal 2026 guidance was reaffirmed without incorporating any contribution from the $1.1 billion EyeSouth acquisition, suggesting conservative near-term financial expectations.
The transaction remains subject to customary closing conditions and regulatory approvals, which could introduce delays or uncertainty to the completion of the deal.
While the acquisition is expected to be slightly accretive to adjusted diluted EPS within the first 12 months, the magnitude of growth may not offset the high integration costs and risks.
Kultura Brands, Inc., formerly known as Labor Smart INC. (OTCID: LTNC), announced on March 24, 2026, its expanded participation in Cencora Marketplace's Spring & Summer Growth Acceleration Program. This strategic initiative is designed to accelerate the adoption of its Thirst Responder brand and broader portfolio across the U.S. pharmacy channel during a critical purchasing cycle that runs throughout April. The program aims to position Kultura Brands' high-growth beverage and functional wellness brands for increased demand ahead of seasonal peaks such as summer travel, spring wellness resets, and major retail holidays including Mother's Day, Father's Day, and Memorial Day. According to Cencora Marketplace data from the 2025 event, total sales and order volume increased by 71 percent year-over-year, while unique products purchased grew by 40 percent, reflecting a clear market shift toward innovation and premium product assortments within pharmacies.
Brad Wyatt, Chief Executive Officer of Kultura Brands, noted that the company is entering a phase where execution meets scale, placing brands directly in front of pharmacy operators during their purchasing decisions. Brent Albin, Chief Operating Officer, emphasized disciplined execution across supply chain and inventory readiness to drive measurable sell-through and repeat ordering. Michael Derrick, Chief Marketing Officer, highlighted an intentional focus on building brand equity with a goal toward conversion and retention rather than short-term awareness, aiming to reinforce Thirst Responder's positioning as a premium functional hydration product. The company stated it expects this program to drive increased product trial, expand retail penetration, and support continued growth throughout 2026.
Kultura Brands continues to build momentum with Thirst Responder gaining traction as a differentiated hydration solution and its Adios brand expanding within the premium ready-to-drink category. These efforts are supported by national distribution relationships, strategic marketing initiatives, and a disciplined approach to execution at the store level, including expanded distribution agreements and increased retail placements. The company remains committed to driving long-term shareholder value through disciplined execution, strategic partnerships, and scalable brand development across beverage, functional wellness, and lifestyle categories. While these forward-looking statements include expectations for growth and distribution expansion based on current conditions, they are subject to risks such as market conditions, competitive pressures, supply chain constraints, and regulatory developments that could cause actual results to differ materially from projections.
π Program runs April 2026 targeting seasonal travel and wellness demand.
π Past events drove 71% sales growth and 40% unique product purchases.
πΌ Leadership focuses on disciplined execution and long-term brand equity over short-term gains.
π€ Kultura Brands, Inc., formerly Labor Smart INC, has announced expanded participation in Cencora's Spring & Summer Growth Acceleration Program to drive adoption across U.S. pharmacies.
π The program runs throughout April 2026, targeting key seasonal demand periods like summer travel and spring wellness resets.
π According to Cencora Marketplace data from the previous 2025 event, total sales and order volume increased by 71%, while unique product purchases grew by 40%.
π΄ Thirst Responder is being prioritized to expand its footprint within the pharmacy channel as consumer demand for functional hydration rises.
π§ The company aims to align with increasing demand for electrolyte replenishment and performance-driven wellness products through this initiative.
πΌ Brad Wyatt, CEO of Kultura Brands, stated that execution meets scale, placing brands directly in front of pharmacy operators during critical purchasing decisions.
π¦ Brent Albin, COO, emphasized disciplined execution across supply chain, inventory readiness, and retail alignment to drive measurable sell-through and repeat ordering.
π― Michael Derrick, CMO, highlighted the focus on building brand equity with conversion and retention rather than just short-term awareness.
π·οΈ The broader Kultura portfolio includes brands like Adios expanding within the premium ready-to-drink category alongside Thirst Responder.
π Participation in the Cencora program is expected to drive increased product trial, expand retail penetration, and support continued growth throughout 2026.
π’ Kultura Brands is a publicly traded platform focused on beverage, functional wellness, and lifestyle categories with operations across retail and e-commerce.
β οΈ The announcement includes forward-looking statements regarding anticipated growth, distribution expansion, and future financial results subject to risks and uncertainties.
Bullish Signals
Cencora sales grew 71% year-over-year with 40% unique product growth.
Portfolio gains traction as premium functional hydration solutions in U.S. pharmacies.
Execution validates platform strength through strong distribution momentum and scale.
Disciplined supply chain readiness supports sustained national growth targets for 2026.
Building brand equity to drive trial and expand retail penetration.
Risk Factors
Future results risk material variance due to market, competition, supply chain, regulatory, and execution issues.
Recent renaming from Labor Smart (OTCID: LTNC) suggests potential corporate restructuring or instability.
Capital constraints may hinder high-growth strategies, acquisitions, and brand development funding.
Data relies on Cencora without disclosing specific Kultura Brands sales or revenue figures.
Bullish Signals
Kultura Brands announced expanded participation in Cencora's Spring & Summer Growth Acceleration Program, positioning its Thirst Responder and broader portfolio for accelerated adoption across U.S. pharmacy channels.
Cencora Marketplace data from the 2025 Spring & Summer event showed total sales and order volume increased by 71 percent compared to the prior year, while unique products purchased grew by 40 percent.
The program aligns with increasing consumer demand for functional hydration and wellness products during key seasonal periods including summer travel and major retail holidays.
CEO Brad Wyatt stated that execution meets scale in their current phase, validating the strength of their platform and relevance of their brands through distribution momentum.
COO Brent Albin highlighted disciplined execution across supply chain and inventory readiness designed to support sustained national growth.
CMO Michael Derrick emphasized building brand equity with a focus on conversion and retention, reinforcing Thirst Responder's positioning as a premium functional hydration product.
Kultura Brands' portfolio includes Thirst Responder and Adios, both gaining traction as differentiated hydration solutions within the premium ready-to-drink category.
The company expects participation in the program to drive increased product trial, expand retail penetration, and support continued growth throughout 2026.
Risk Factors
Forward-looking statements regarding anticipated growth, distribution expansion, and future financial results are subject to risks such as market conditions, competitive pressures, supply chain constraints, regulatory developments, and execution risks which could cause actual results to differ materially.
The company is a newly renamed entity (formerly known as Labor Smart INC with OTCID:LTNC), which may indicate recent restructuring or instability in its corporate history.
Capital availability is explicitly cited as a risk factor that could impact the company's ability to sustain high-growth strategies and fund acquisitions or brand development initiatives.
The announcement relies on third-party marketplace data from Cencora without disclosing specific sales figures or revenue growth for Kultura Brands itself in this period.
TimesSquare Capital Management released its fourth-quarter 2025 investor letter for the U.S. Focus Growth Strategy, which noted that the strategy returned -3.55% gross and -3.76% net during the quarter compared to a -3.70% return for the Russell Midcap Growth Index. Over the full year of 2025, the strategy delivered a 14.84% gross return against an 8.66% gain for the index. The firm highlighted its top five holdings and specifically discussed its position in Cencora, Inc., trading under the NYSE ticker COR. According to the letter, TimesSquare Capital prefers health care stocks that offer novel therapies for unmet needs with premium pricing or specialized service providers. Cencora is classified as a pharmaceutical sourcing and distribution company, and the stock gained 8% over the period covered in the report.
The letter cites specific financial data regarding Cencora, noting that its fiscal fourth-quarter earnings exceeded consensus estimates due to strength in U.S. business offsetting a miss in international operations. Management at Cencora had also announced consideration of strategic alternatives for the animal health and non-core portions of its PharmaLex business. As of March 19, 2026, Cencora shares closed at $331.74, reflecting a one-month return of -8.13% but a 52-week gain of 24.05%. The company's market capitalization is approximately $64.53 billion. Data from TimesSquare shows that 61 hedge fund portfolios held Cencora at the end of the fourth quarter, an increase from 59 portfolios in the previous quarter.
Despite the positive performance and increased institutional holdings, TimesSquare Capital indicated it does not currently list Cencora among its top picks compared to certain AI stocks, which the firm believes offer greater upside potential with less downside risk. The first quarter of fiscal 2026 saw Cencora's consolidated revenue increase by 5.5% year-over-year to $85.9 billion driven by solid growth in both reportable segments. The article concludes by directing readers to additional resources on best healthcare stocks for 2026 and a broader collection of Q4 2025 investor letters, while noting the disclosure that no conflicts were present with the original publication at Insider Monkey.
π COR shares surged 8% after Q4 earnings beat and hedge fund interest grew.
Consolidated revenue increased 5.5% year-over-year to $85.9 billion in Q1 fiscal 2026, driven by solid growth in both reportable segments.
Hedge fund interest remains strong with 61 portfolios holding the stock at the end of the fourth quarter, up from 59 in the previous quarter.
The company's strategic consideration of alternatives for non-core parts of its PharmaLex business suggests active management focused on core value drivers.
Risk Factors
Although fiscal Q4 earnings outpaced estimates, the strength was offset by a miss in international business, indicating geographic concentration risk.
The management team is considering strategic alternatives for the animal health and non-core parts of its PharmaLex business, which could lead to asset sales or restructuring uncertainty.
Cencora Inc. is not included in the fund's list of 40 Most Popular Stocks Ahead of 2026, suggesting relative lack of conviction compared to peers.
The investment manager explicitly believes certain AI stocks offer greater upside potential and carry less downside risk than Cencora Inc., signaling a shift in capital allocation away from the company.
Cencora Inc. was absent from the fund's top holdings despite being a preferred healthcare name, implying it may fall below their investment threshold for 2026.
One-month return of Cencora Inc. was negative at -8.13%, showing recent price weakness that contrasts with the stock gaining 24.05% over the past 52 weeks.
Cencora, Inc. (COR) held a presentation at the Leerink Global Healthcare Conference 2026 on March 10, 2026, providing an update on its financial performance and strategic acquisitions. During the session, Jim Cleary, the Chief Financial Officer, highlighted that the company's U.S. segment experienced significant growth in the most recent quarter, reporting a 21% increase in activity. This positive momentum was attributed to underlying business trends, though specific revenue figures for the quarter were not detailed in the provided transcript excerpt.
A key strategic development discussed was the acquisition of additional assets to strengthen Cencora's Medical Specialty Operator (MSO) portfolio. The company confirmed that it had officially closed its purchase of the remaining portion of OneOncology, a move that follows their previous acquisition of Retina Consultants of America. Executives expressed strong satisfaction with this consolidation, noting that owning both entities allows them to fully capitalize on opportunities within the specialty care distribution model. This ownership structure is expected to drive future growth and provide Cencora with deeper integrations across oncology and retina care markets.
The presentation emphasized the company's confidence in its strategic direction following these acquisitions, suggesting that the combination of strong organic growth in the U.S. sector and successful portfolio expansion positions Cencora well for the upcoming fiscal year. While specific guidance numbers or long-term financial targets were not explicitly quantified in the available text, the management team reiterated their commitment to executing on their MSO strategy to generate value for shareholders.
π Cencora's U.S. segment grew 21% in the most recent quarter.
β OneOncology acquisition finalized, confirming full MSO ownership strategy.
π€ CFO Jim Cleary and SVP Ben Murphy joined for March 2026 conference.
π Cencora, Inc. (COR) reported a 21% growth in its U.S. segment during the most recent quarter.
π° The company successfully closed on an acquisition of the portion of OneOncology it did not previously own.
π₯ Executives confirmed ownership of both Retina Consultants of America and OneOncology under their MSO strategy.
π€ Jim Cleary, CFO, and Ben Murphy, SVP of IR, joined Michael Cherny from Leerink for the presentation.
π The presentation took place on March 10, 2026, at the Leerink Global Healthcare Conference 2026.
πΌ Bennett Murphy serves as Senior VP of Investor Relations and handles Enterprise Productivity and Treasury.
π Jim Cleary is the Chief Financial Officer providing an overview of recent quarter performance.
π The U.S. segment growth highlights a strong underlying trend for the business in the last quarter.
Bullish Signals
Cencora (COR) U.S. segment grew 21% last quarter.
Acquisition closed for Q1 2026.
Owns both Retina Consultants of America and OneOncology.
Strengthens MSO strategy.
Bullish Signals
Cencora, Inc. (COR) reported a 21% growth in its U.S. segment during the most recent quarter.
The company highlighted this strong trend as a key driver of underlying business health.
Cencora announced and closed the acquisition of OneOncology in Q1 2026.
The company now owns both Retina Consultants of America and OneOncology, strengthening its MSO strategy.
Risk Factors
The article focuses primarily on strong growth trends and positive acquisitions (21% growth in the U.S. segment, closure of OneOncology acquisition), offering no negative aspects or risks to summarize.
No downside catalysts, regulatory concerns, declining metrics, or competitive threats are mentioned in the provided transcript excerpt.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)